The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, which received accelerated FDA approval last week.
The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer and thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The biotech company announced data from its Phase I/II study of pralsetinib in RET fusion-positive non-small cell lung cancer and kicked off a rolling submission for FDA approval. Eli Lilly Oncology announced data for its own RET inhibitor in September.
The trial is the second Phase III study of the RET inhibitor selpercatinib, which Lilly acquired when it bought Loxo Oncology at the beginning of this year for $8 billion.
Analysts nevertheless wrote that with each data update, Lilly's RET inhibitor LOXO-292 (selpercatinib) appears less differentiated on efficacy as well as tolerability from Blueprint Medicines' BLU-667 (pralsetinib).